Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 6:29 a.m.

    📋 IMAGO BIOSCIENCES, INC. (IMGO) - Clinical Trial Update

    Filing Date: 2022-06-13

    Accepted: 2022-06-13 06:07:11

    Event Type: Clinical Trial Update

    Event Details:

    Imago Biosciences Inc (the company became a subdivision of the company Merck (NYSE: MRK)) (IMGO) Announces Clinical Trial Update Imago Biosciences Inc (the company became a subdivision of the company Merck (NYSE: MRK)) (IMGO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: path, expressed
    • Clinical Stage: clinical trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
      • planned for 2H22 Pivotal study for ET planned Cash runway into 2025
      • planned for 2H 2022
      • targeting specific platelet counts in MF and ET Clinical improvement in a majority of MPN patients No progression to AML in a high-risk MF patient population Potential use for the treatment of PV Potential for use in combinations for hematologic neoplasms and solid tumors CTP-101 – R/R AML/MDS study completed CTP-102 Advanced MF – on-study patients all enrolled in Extension study (CTP-202) after 1 year CTP-103 Food Effect – completed CTP-104 Mass Balance – completed CTP-105 DDI – FPFV planned for 2H2022

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Imago Biosciences Inc (the company became a subdivision of the company Merck (NYSE: MRK))
    • CIK: 0001623715
    • Ticker Symbol: IMGO
    • Period End Date: 2022-06-11
    • Document Type: 8-K

Search

News categories